ArticleBMJ open2026

Rezvilutamide in combination with androgen deprivation therapy (ADT) with or without docetaxel in the neoadjuvant treatment of oligometastatic prostate cancer (REDOOM): study protocol for an open-label, parallel-cohort, multicentre clinical study.

Zi-Jian Chen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.